185 related articles for article (PubMed ID: 16609051)
1. Early-stage melanoma: staging criteria and prognostic modeling.
Ross MI
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2312s-2319s. PubMed ID: 16609051
[TBL] [Abstract][Full Text] [Related]
2. Classification and staging of melanoma.
Gershenwald JE; Buzaid AC; Ross MI
Clin Lab Med; 2000 Dec; 20(4):785-815. PubMed ID: 11221515
[TBL] [Abstract][Full Text] [Related]
3. New American Joint Commission on Cancer staging system for melanoma: prognostic impact and future directions.
Ross MI
Surg Oncol Clin N Am; 2006 Apr; 15(2):341-52. PubMed ID: 16632219
[TBL] [Abstract][Full Text] [Related]
4. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
[TBL] [Abstract][Full Text] [Related]
5. Estimates of stage-specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma.
Ben-Porat L; Panageas KS; Hanlon C; Patel A; Halpern A; Houghton AN; Coit D
Cancer; 2006 Jan; 106(1):163-71. PubMed ID: 16331596
[TBL] [Abstract][Full Text] [Related]
6. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
[TBL] [Abstract][Full Text] [Related]
7. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
8. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
[TBL] [Abstract][Full Text] [Related]
9. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
Eigentler TK; Buettner PG; Leiter U; Garbe C;
J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
[TBL] [Abstract][Full Text] [Related]
10. New TNM melanoma staging system: linking biology and natural history to clinical outcomes.
Balch CM; Buzaid AC; Soong SJ; Atkins MB; Cascinelli N; Coit DG; Fleming ID; Gershenwald JE; Houghton A; Kirkwood JM; McMasters KM; Mihm MF; Morton DL; Reintgen DS; Ross MI; Sober A; Thompson JA; Thompson JF
Semin Surg Oncol; 2003; 21(1):43-52. PubMed ID: 12923915
[TBL] [Abstract][Full Text] [Related]
11. Impact of false-negative sentinel lymph node biopsy on survival in patients with cutaneous melanoma.
Caracò C; Marone U; Celentano E; Botti G; Mozzillo N
Ann Surg Oncol; 2007 Sep; 14(9):2662-7. PubMed ID: 17597345
[TBL] [Abstract][Full Text] [Related]
12. Molecular staging for patients with malignant melanoma.
Shivers S; Jakub J; Pendas S; Reintgen D
Expert Rev Anticancer Ther; 2007 Nov; 7(11):1665-74. PubMed ID: 18020932
[TBL] [Abstract][Full Text] [Related]
13. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
14. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes.
van Akkooi AC; Nowecki ZI; Voit C; Schäfer-Hesterberg G; Michej W; de Wilt JH; Rutkowski P; Verhoef C; Eggermont AM
Ann Surg; 2008 Dec; 248(6):949-55. PubMed ID: 19092339
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study.
Koskivuo I; Talve L; Vihinen P; Mäki M; Vahlberg T; Suominen E
Ann Surg Oncol; 2007 Dec; 14(12):3566-74. PubMed ID: 17924169
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of molecular staging study of sentinel lymph nodes by reverse transcriptase-polymerase chain reaction for tyrosinase in melanoma patients.
Mangas C; Hilari JM; Paradelo C; Rex J; Fernández-Figueras MT; Fraile M; Alastrue A; Ferrándiz C
Ann Surg Oncol; 2006 Jul; 13(7):910-8. PubMed ID: 16788751
[TBL] [Abstract][Full Text] [Related]
17. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma.
Aloia TA; Gershenwald JE; Andtbacka RH; Johnson MM; Schacherer CW; Ng CS; Cormier JN; Lee JE; Ross MI; Mansfield PF
J Clin Oncol; 2006 Jun; 24(18):2858-65. PubMed ID: 16782925
[TBL] [Abstract][Full Text] [Related]
18. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma.
Page AJ; Carlson GW; Delman KA; Murray D; Hestley A; Cohen C
Am Surg; 2007 Jul; 73(7):674-8; discussion 678-9. PubMed ID: 17674939
[TBL] [Abstract][Full Text] [Related]
19. Our experience of melanoma thickness as a predictor of outcome of sentinel node biopsy.
Homolak D; Vucetić B; Puljiz Z; Blajć I; Vurnek Zivković M; Situm M
Coll Antropol; 2008 Oct; 32 Suppl 2():57-60. PubMed ID: 19138008
[TBL] [Abstract][Full Text] [Related]
20. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma.
Scheri RP; Essner R; Turner RR; Ye X; Morton DL
Ann Surg Oncol; 2007 Oct; 14(10):2861-6. PubMed ID: 17882497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
